October 27, 2020
Hemophilia

Hemophilia Market is Estimated to Achieve $ 17 Billion by 2026

Introduction

The global Hemophilia Market is analysed to grow at a CAGR of around 5.3% during the forecast period and projected to reach the market value over US$ 17 Bn in 2026. The study provides an extensive market evaluation and includes thorough ideas, facts, historical information, and statistically backed and industry-validated market data. It also includes predictions using appropriate hypotheses and methodologies. Moreover, the research report provides analysis and information according to categories such as type, applications, and geographic regions.

Regional Outlook

Depending on geographic regions, global Hemophilia Market is segmented into key regions: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. As of 2018, the worldwide Hemophilia Market dominated by North America in terms of market revenue. The Asia-Pacific region, on the other side, is expected to grow at highest CAGR during the forecast period. Different Asia-Pacific countries, mostly China, Japan and India, are important elements of regional development that thus affect the worldwide Hemophilia Market.

Click To Get!!! FREE!!! Sample Report Pages (Including Full TOC, Table & Figures)

Scope of the Report:

The report first uses historic data from different companies. The data collected is used to analyses the growth of industries in the past years. It includes data from the year 2015 to the year 2018. The forecast data provides the reader with an understating of the future of the market. The same data is used to predict the expectation of the companies and how they are expected to evolve in the coming years. The research provides historical as well as estimated data from the year 2018 to 2026. The details in the report give a brief overview of the market by examining its historical data, the current data, and forecast data to understand the growth of the market.

Competitive Landscape

The competition witnessed in the market is soaring. With rising demand for innovation, players are experimenting with various strategies to gain competitive edge and strengthen their foothold in the market. Several companies operating in the industry are looking at expanding their footprint across emerging nations to capitalize on the prevailing opportunities there. The gap in demand and supply of healthcare facilities in underdeveloped countries has resulted in the presence of unmet demand in these countries. These companies are looking at capitalizing on this to emerge at the fore of the global market.

Growth strategies adopted by the companies operating in the market are examined in detail. This is done to study how these strategies influence on this market. Furthermore, the bargaining power of suppliers and buyers. Furthermore, it reveals threat from new entrants and available substitute products.

Key Players

Profile of the key players in the global Hemophilia Market will be provided, which include key financials, new developments and business strategies. These players contribute a major proportion towards market growth. Moreover, the industry’s present and future business perspective for latest innovations (including development possibilities and drivers, as well as difficulties and constraints for both emerged and emerging economies). This report also helps to analyse stakeholder market opportunities by identifying the high growth segments. On the other hand, few players of the Hemophilia Market emphasize their regional presence in co-operation with retailers. The research also involves incisive competitive landscape and offers market players with important suggestions on effective imperatives and strategies. Competitive Landscape is included to provide a dashboard perspective for report viewers and access key differentiators among competitor companies.

The market share of the global Hemophilia Market is dominated by companies like Baxalta, CSL Behring, Pfizer, Inc., Bayer Healthcare, BioMarin Pharmaceutical, Inc., Biogen, Chugai Pharmaceutical Co., Novo Nordisk, Shire Plc., and others.

Key Segments

The report segments the market into various categories. The leading segments within each category are identified in the report. Furthermore, it calculates market share that these segments hold. Factors enabling growth in these segments are studied in detail. The report also reveals the factors that may restrain the market growth in these categories.

Market Segmentation

Market By Type

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C

Market By Treatment

  • On-demand
  • Prophylaxis

Market By Therapy

  • Replacement Therapy
  • Gene Therapy

Market By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Regional Insights

Considering the demand for Hemophilia, the North America region is dominating the hemophilia market in 2018. The North America region is predicted to continue its dominance over the end of the forecast period by holding the share of more 35%. The increasing inclination toward treatment of prophylaxis is expected to be the key factordriving the growth in this region.

  • According to a global survey conducted by WHF (World Federation of Hemophilia)in 2015, approximately 63.0% of the patients in the U.S. have opted for prophylaxis treatment. The adoption of such treatment options is resulting in the acceleration of the market.

Among the other regions, the Asia-Pacific region is anticipated to witness the substantial growth over the forecast period by registering the highest CAGR growth. Increasing awareness about hemophilia among the emerging countries including India, Indonesia, Malaysia, Japan, and others is expected to boost the market growth. In addition, the increasing disposable income backed by the advancements in the medicinal treatments such as the use of therapies for the treatment of hemophilia disorder is fuelling the demand for hemophilia.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Hemophilia
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Hemophilia Market By Type
1.2.2.1. Global Hemophilia Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Hemophilia Market Revenue Share By Type in 2017
1.2.2.3. Hemophilia A
1.2.2.4. Hemophilia B
1.2.2.5. Hemophilia C
1.2.2.6. Others
1.2.3. Hemophilia Market By Treatment
1.2.3.1. Global Hemophilia Market Revenue and Growth Rate Comparison By Treatment (2015-2026)
1.2.3.2. On-demand
1.2.3.3. Prophylaxis
1.2.3.4. Others
1.2.4. Hemophilia Market By Therapy
1.2.4.1. Global Hemophilia Market Revenue and Growth Rate Comparison By Therapy (2015-2026)
1.2.4.2. Replacement Therapy
1.2.4.3. Gene Therapy
1.2.4.4. Others
1.2.5. Hemophilia Market by Geography
1.2.5.1. Global Hemophilia Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Hemophilia Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Hemophilia Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Hemophilia Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Hemophilia Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Hemophilia Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Hemophilia Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Hemophilia Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Hemophilia Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Hemophilia Major Manufacturers in 2017

CHAPTER 4. HEMOPHILIA MARKET BY TYPE

4.1. Global Hemophilia Revenue By Type
4.2. Hemophilia A
4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.3. Hemophilia B
4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.4. Hemophilia C
4.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.5. Other
4.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 5. HEMOPHILIA MARKET BY TREATMENT

5.1. Global Hemophilia Revenue By Treatment
5.2. On-demand
5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.3. Prophylaxis
5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.4. Others
5.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 6. HEMOPHILIA MARKET BY THERAPY

6.1. Global Hemophilia Revenue By Therapy
6.2. Replacement Therapy
6.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.3. Gene Therapy
6.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.4. Others
6.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 7. NORTH AMERICA HEMOPHILIA MARKET BY COUNTRY

7.1. North America Hemophilia Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.2. North America Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Hemophilia Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
7.3.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
7.3.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
7.4.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
7.4.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
7.5.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
7.5.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)

CHAPTER 8. EUROPE HEMOPHILIA MARKET BY COUNTRY

8.1. Europe Hemophilia Market Revenue and Growth Rate, 2015 – 2026 ($Million)
8.2. Europe Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.3.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
8.3.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.4.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
8.4.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.5.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
8.5.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.6.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
8.6.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
8.7.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
8.7.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC HEMOPHILIA MARKET BY COUNTRY

9.1. Asia-Pacific Hemophilia Market Revenue and Growth Rate, 2015 – 2026 ($Million)
9.2. Asia-Pacific Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.3.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
9.3.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.4.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
9.4.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.5.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
9.5.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.6.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
9.6.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.7.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
9.7.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
9.8.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
9.8.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)

CHAPTER 10. LATIN AMERICA HEMOPHILIA MARKET BY COUNTRY

10.1. Latin America Hemophilia Market Revenue and Growth Rate, 2015 – 2026 ($Million)
10.2. Latin America Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.3.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
10.3.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.4.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
10.4.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
10.5.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
10.5.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)

CHAPTER 11. MIDDLE EAST HEMOPHILIA MARKET BY COUNTRY

11.1. Middle East Hemophilia Market Revenue and Growth Rate, 2015 – 2026 ($Million)
11.2. Middle East Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.3.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
11.3.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.4.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
11.4.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
11.5.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
11.5.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)

CHAPTER 12. AFRICA HEMOPHILIA MARKET BY COUNTRY

12.1. Africa Hemophilia Market Revenue and Growth Rate, 2015 – 2026 ($Million)
12.2. Africa Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
12.3.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
12.3.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
12.4.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
12.4.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Type, 2015 – 2026 ($Million)
12.5.2. Market Revenue and Forecast By Treatment, 2015 – 2026 ($Million)
12.5.3. Market Revenue and Forecast By Therapy, 2015 – 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. Baxalta
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. CSL Behring
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Pfizer, Inc.
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Bayer Healthcare
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. BioMarin Pharmaceutical, Inc.
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Biogen
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Chugai Pharmaceutical Co.
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Novo Nordisk
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Shire Plc.
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies
13.10. Others
13.10.1. Company Snapshot
13.10.2. Overview
13.10.3. Financial Overview
13.10.4. Type Portfolio
13.10.5. Key Developments
13.10.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

The report is readily available and can be dispatched immediately after payment confirmation.

To Purchase this Premium Report@ https://www.acumenresearchandconsulting.com/buy-now/0/1239

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact-based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Contact Us:

Phone: +14079154157 | +14089009135
Email:
sales@acumenresearchandconsulting.com
Website: https://www.acumenresearchandconsulting.com
Follow Us: 
LinkedIN Twitter

Saurabh

Saurabh is an SEO Analyst professional, working on a large marketing and sales platform that helps firms attract visitors and close customers. Proficient in monitoring and evaluating search results and search performance across the major search channels. With his strong analytical skills. Saurabh covers healthcare, technological, chemical, lifestyle and trendy news from all over the world.

View all posts by Saurabh →

Leave a Reply

Your email address will not be published. Required fields are marked *